Cynata Therapeutics (ASX:CYP) completed the final participant visits in its pivotal phase 3 SCUIpTOR trial of CYP-004 for knee osteoarthritis, marking the end of the two-year follow-up, according to a Monday filing with the Australian bourse.
The University of Sydney will complete data monitoring and quality checks, with the trial results anticipated in the second quarter of 2026, the filing added.
The company's shares rose around 6% in recent Monday trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.